ATE308754T1 - Effiziente anreicherung und detektion von ausgesäten tumorzellen - Google Patents

Effiziente anreicherung und detektion von ausgesäten tumorzellen

Info

Publication number
ATE308754T1
ATE308754T1 AT96929049T AT96929049T ATE308754T1 AT E308754 T1 ATE308754 T1 AT E308754T1 AT 96929049 T AT96929049 T AT 96929049T AT 96929049 T AT96929049 T AT 96929049T AT E308754 T1 ATE308754 T1 AT E308754T1
Authority
AT
Austria
Prior art keywords
tumor cells
cells
detection
efficient enrichment
separated
Prior art date
Application number
AT96929049T
Other languages
English (en)
Inventor
Jurgen Schmitz
Stefan Miltenyi
Fawn Qian
Aaron Kantor
Original Assignee
Miltenyi Biotec Gmbh
Amcell Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27060032&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE308754(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Miltenyi Biotec Gmbh, Amcell Corp filed Critical Miltenyi Biotec Gmbh
Application granted granted Critical
Publication of ATE308754T1 publication Critical patent/ATE308754T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326—Magnetic particles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/962—Prevention or removal of interfering materials or reactants or other treatment to enhance results, e.g. determining or preventing nonspecific binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/824—Immunological separation techniques
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/825—Pretreatment for removal of interfering factors from sample

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT96929049T 1995-08-28 1996-08-23 Effiziente anreicherung und detektion von ausgesäten tumorzellen ATE308754T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52004995A 1995-08-28 1995-08-28
US08/667,464 US6190870B1 (en) 1995-08-28 1996-06-21 Efficient enrichment and detection of disseminated tumor cells
PCT/US1996/013704 WO1997008557A1 (en) 1995-08-28 1996-08-23 Efficient enrichment and detection of disseminated tumor cells

Publications (1)

Publication Number Publication Date
ATE308754T1 true ATE308754T1 (de) 2005-11-15

Family

ID=27060032

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96929049T ATE308754T1 (de) 1995-08-28 1996-08-23 Effiziente anreicherung und detektion von ausgesäten tumorzellen

Country Status (7)

Country Link
US (2) US6190870B1 (de)
EP (1) EP0850417B2 (de)
AT (1) ATE308754T1 (de)
AU (1) AU6859696A (de)
CA (1) CA2229001A1 (de)
DE (1) DE69635377T3 (de)
WO (1) WO1997008557A1 (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19736691A1 (de) * 1997-08-22 1999-02-25 Michael Prof Dr Med Giesing Verfahren zur Charakterisierung und Identifizierung disseminierter und metastasierter Krebszellen
WO1999041613A1 (en) 1998-02-12 1999-08-19 Immunivest Methods and reagents for the rapid and efficient isolation of circulating cancer cells
DE60044236D1 (de) 1999-02-17 2010-06-02 Csl Ltd Immunogene komplexe und methoden in bezug auf diese
EP1210597A4 (de) * 1999-07-19 2003-03-12 Chromavision Med Sys Inc Zellanreicherung
EP1207961B1 (de) * 1999-09-03 2006-03-15 Miltenyi Biotec GmbH Verfahren zur modifikation von ausgewählten zellen in einer magnetischen zelltrennungsäule
EP1311820B1 (de) * 2000-07-14 2015-02-11 Janssen Diagnostics, LLC Erhöhte trenneffizienz über gesteuerte aggregation magnetischer nanopartikel
US6576423B2 (en) * 2000-12-08 2003-06-10 The Board Of Regents Of The University Of Nebraska Specific mucin expression as a marker for pancreatic cancer
BR0207290A (pt) * 2001-02-16 2005-06-07 Immunivest Corp Método para analisar um paciente quanto à presença de uma malignidade, célula maligna isolada das células cultivadas, vacina de tumor, molécula associada com diátese de tumor alterada, métodos para determinar alterações em moléculas associadas com diátese de tumor como um meio para predizer a eficácia da terapia, como um meio para analisar dosagem apropriada para terapia, como um meio para monitorar eficácia da terapia, como um meio para analisar progressão de câncer, para realizar uma biópsia de corpo inteiro em um paciente, e para identificar alterações em uma célula de tumor circulante relativamente a células presentes numa massa de tumor in situ, e, kit de teste para analisar uma amostra de paciente quanto à presença de uma célula maligna não-hematopoiética
DE10127079A1 (de) * 2001-06-02 2002-12-12 Ulrich Pachmann Verfahren zum quantitativen Nachweis vitaler epithelialer Tumorzellen in einer Körperflüssigkeit
US7731648B2 (en) * 2001-07-25 2010-06-08 Aduro Biotech Magnetic nanoscale particle compositions, and therapeutic methods related thereto
US6997863B2 (en) * 2001-07-25 2006-02-14 Triton Biosystems, Inc. Thermotherapy via targeted delivery of nanoscale magnetic particles
US7074175B2 (en) 2001-07-25 2006-07-11 Erik Schroeder Handy Thermotherapy via targeted delivery of nanoscale magnetic particles
US7951061B2 (en) * 2001-07-25 2011-05-31 Allan Foreman Devices for targeted delivery of thermotherapy, and methods related thereto
WO2003019141A2 (en) * 2001-08-23 2003-03-06 Immunivest Corporation Analysis of circulating tumor cells, fragments, and debris
US7863012B2 (en) * 2004-02-17 2011-01-04 Veridex, Llc Analysis of circulating tumor cells, fragments, and debris
AU2002327704A1 (en) * 2001-09-21 2003-04-01 Raven Biotechnologies, Inc. Antibodies that bind to cancer-associated antigen cytokeratin 8 and methods of use thereof
US8980568B2 (en) * 2001-10-11 2015-03-17 Aviva Biosciences Corporation Methods and compositions for detecting non-hematopoietic cells from a blood sample
US8986944B2 (en) 2001-10-11 2015-03-24 Aviva Biosciences Corporation Methods and compositions for separating rare cells from fluid samples
US20060210555A1 (en) * 2001-12-21 2006-09-21 Antigenics, Inc. Compositions comprising immunoreactive reagents and saponins, and methods of use thereof
US8313742B2 (en) * 2002-03-29 2012-11-20 Depuy Acromed, Inc. Cell-containing bone graft material
US20060008807A1 (en) * 2002-08-23 2006-01-12 O'hara Shawn M Multiparameter analysis of comprehensive nucleic acids and morphological features on the same sample
EP1566639A4 (de) * 2002-11-08 2006-10-11 Hiroshi Takahashi Verfahren zur untersuchung von krebszellen und reagens dafür
US20040156846A1 (en) * 2003-02-06 2004-08-12 Triton Biosystems, Inc. Therapy via targeted delivery of nanoscale particles using L6 antibodies
SE0302074D0 (sv) * 2003-07-15 2003-07-15 Simon Ekstroem Device and method for analysis of samples using a combined sample treatment and sample carrier device
CA2535153A1 (en) * 2003-08-12 2005-05-19 Massachusetts Institute Of Technology Sample preparation methods and devices
US20050277204A1 (en) * 2003-08-12 2005-12-15 Massachusetts Institute Of Technology Sample preparation methods and devices
US20050181353A1 (en) * 2004-02-17 2005-08-18 Rao Galla C. Stabilization of cells and biological specimens for analysis
US9790539B2 (en) * 2004-06-30 2017-10-17 Russell Biotech, Inc. Methods and reagents for improved selection of biological molecules
US20060040389A1 (en) * 2004-08-17 2006-02-23 Murry Charles E Purified compositions of stem cell derived differentiating cells
JP4798801B2 (ja) * 2004-10-06 2011-10-19 ウェルスタット バイオロジクス コーポレイション 循環する癌細胞におけるＨｅｒ−２／ｎｅｕタンパク質のレベルの上昇の検出および処置
US7901950B2 (en) * 2005-08-12 2011-03-08 Veridex, Llc Method for assessing disease states by profile analysis of isolated circulating endothelial cells
JP4902674B2 (ja) * 2006-03-09 2012-03-21 エフ．ホフマン−ラ ロシュ アーゲー 抗薬物抗体アッセイ法
WO2008060687A2 (en) * 2006-05-12 2008-05-22 San Diego State University Research Foundation High-throughput methods for quantifying cells in environmental and laboratory samples
EP2029779A4 (de) 2006-06-14 2010-01-20 Living Microsystems Inc Verwendung hoch paralleler snp-genotypisierung zur fötalen diagnose
WO2008111990A1 (en) * 2006-06-14 2008-09-18 Cellpoint Diagnostics, Inc. Rare cell analysis using sample splitting and dna tags
US20080050739A1 (en) 2006-06-14 2008-02-28 Roland Stoughton Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats
US8372584B2 (en) 2006-06-14 2013-02-12 The General Hospital Corporation Rare cell analysis using sample splitting and DNA tags
US9277295B2 (en) * 2006-06-16 2016-03-01 Cisco Technology, Inc. Securing media content using interchangeable encryption key
CA2657621A1 (en) * 2006-07-14 2008-01-17 Aviva Biosciences Corporation Methods and compositions for detecting rare cells from a biological sample
MX2009002397A (es) * 2006-09-05 2009-03-16 Veridex Llc Metodos para clasificar imagenes celulares.
EP2145188A4 (de) * 2007-04-19 2010-06-30 Wellstat Biologics Corp Nachweis von her2/neu-protein aus nichtisolierten zirkulierenden krebszellen und behandlung
US8071395B2 (en) * 2007-12-12 2011-12-06 The Board Of Trustees Of The Leland Stanford Junior University Methods and apparatus for magnetic separation of cells
US8008032B2 (en) 2008-02-25 2011-08-30 Cellective Dx Corporation Tagged ligands for enrichment of rare analytes from a mixed sample
US20100099074A1 (en) * 2008-07-25 2010-04-22 Garry Nolan Collection device and method for stimulating and stabilizing a biological sample
US9459246B2 (en) 2009-09-08 2016-10-04 Nodality, Inc. Induced intercellular communication
US8565892B2 (en) 2009-10-31 2013-10-22 Qteris, Inc. Nanoparticle-sized magnetic absorption enhancers having three-dimensional geometries adapted for improved diagnostics and hyperthermic treatment
KR101122124B1 (ko) * 2009-11-17 2012-03-16 주식회사 아모그린텍 분석물질의 검출 방법 및 장치
US20110312503A1 (en) 2010-01-23 2011-12-22 Artemis Health, Inc. Methods of fetal abnormality detection
US8695618B2 (en) 2010-12-22 2014-04-15 Carnegie Mellon University 3D chemical pattern control in 2D fluidics devices
EP2756005B1 (de) * 2011-09-14 2016-03-02 Abeterno Technologies Limited Intrazelluläre zellenauswahl
CN104620093B (zh) * 2012-08-23 2018-04-20 干细胞技术公司 用于快速可逆生物分子标记的组合物和方法
US10429393B2 (en) 2014-01-20 2019-10-01 National Centre For Cell Science Tumor deconstruction platform for the analysis of intra-tumor heterogeneity
EP4253937A3 (de) 2014-02-26 2023-11-08 Brigham and Women's Hospital, Inc. Verfahren zur zelllevetation und -überwachung
EP2955521A1 (de) * 2014-06-11 2015-12-16 Centre Hospitalier Universitaire Vaudois (CHUV) Verfahren zur Trennung von Zellen
EP3037820A1 (de) 2014-12-27 2016-06-29 Miltenyi Biotec GmbH Zellerkennungsverfahren und Reagenzien mit lösbarem Etikettierungsteil
WO2018227050A1 (en) * 2017-06-09 2018-12-13 The Trustees Of The University Of Pennsylvania Flow cytometry-based platform for the detection, enumeration, and isolation of disseminated tumor cells in bone marrow aspirates
WO2019090062A1 (en) 2017-11-03 2019-05-09 Gray Mark A Quant production and dosing
CN108918871A (zh) * 2018-07-12 2018-11-30 浙江大学 用于外周血循环肿瘤细胞捕获的negFACs-IF:E/M方法
US12023637B2 (en) 2020-03-23 2024-07-02 Mark A. Gray Capillary tube droplet generation systems and methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4965204A (en) * 1984-02-06 1990-10-23 The Johns Hopkins University Human stem cells and monoclonal antibodies
US4935344A (en) * 1984-04-30 1990-06-19 Sloan-Kettering Institute For Cancer Research Method for characterizing types of renal carcinoma and prognosis
US4770183A (en) 1986-07-03 1988-09-13 Advanced Magnetics Incorporated Biologically degradable superparamagnetic particles for use as nuclear magnetic resonance imaging agents
DE3720844A1 (de) * 1987-06-24 1989-01-05 Stefan Miltenyi Trennsaeule fuer die magnetische separierung von zellen, zellaggregaten, und zellulaeren bestandteilen
ATE114507T1 (de) 1988-12-28 1994-12-15 Stefan Miltenyi Verfahren sowie materialien zur hochgraduierten magnetischen abspaltung biologischer materialien.
US5385707A (en) 1988-12-28 1995-01-31 Stefan Miltenyi Metal matrices for use in high gradient magnetic separation of biological materials and method for coating the same
NO180658C (no) * 1994-03-10 1997-05-21 Oeystein Fodstad Fremgangsmåte og anordning for deteksjon av spesifikke målceller i spesialiserte eller blandede cellepopulasjoner og opplösninger som inneholder blandede cellepopulasjoner

Also Published As

Publication number Publication date
US20010000751A1 (en) 2001-05-03
DE69635377D1 (de) 2005-12-08
DE69635377T2 (de) 2006-07-27
US6190870B1 (en) 2001-02-20
WO1997008557A1 (en) 1997-03-06
EP0850417A4 (de) 2001-07-11
EP0850417B1 (de) 2005-11-02
CA2229001A1 (en) 1997-03-06
EP0850417B2 (de) 2009-12-09
EP0850417A1 (de) 1998-07-01
AU6859696A (en) 1997-03-19
DE69635377T3 (de) 2010-07-08

Similar Documents

Publication Publication Date Title
DE69635377D1 (de) Effiziente anreicherung und detektion von ausgesäten tumorzellen
DE69839492D1 (de) Monoklonale antikörper zur apoptosis-induzierung
DK1132097T3 (da) Celle- og serumproteinankere og -konjugater
LV10538A (lv) Imunologiski saistamas vielas noteiksanas panemiens biologiska skidruma un diagnostikas lidzeklis
NO872934D0 (no) Monoklonalt antistoff for utvinning av leukocytter i humant perifert blod og fremgangsmaate for utvinning ved anvendelse av nevnte monoklonale antistoff.
Barnett et al. Antinuclear factors in synovia: Possible participants in the rheumatoid inclusion body
ATE77700T1 (de) Immunkomplextestverfahren.
ES2080047T3 (es) Peptidos hiv y metodos para la deteccion de hiv.
ATE164311T1 (de) Orale, pharmazeutische zusammensetzungen das ein protein oder peptide, eine antikoerper und polymerkugeln enthalten
FR2397449A1 (fr) Produits conjugues chimioluminescents biologiquement actifs et leur utilisation
Schubert Proteins secreted by clonal cell lines: changes in metabolism with culture growth
Postlethwaite et al. Latent lymphokines: isolation of guinea pig latent lymphocyte-derived chemotactic factor for monocytes. Its activation by trypsin and a soluble factor from macrophages
Adelstein et al. Lymphocyte‐Tumor Cell Interaction in Patients with Head and Neck Cancer
DE69026812D1 (de) Konjugate von "pokeweed" antiviralem protein und monoklonalen antikörpern
ES2047946T3 (es) Metodos de cultivos celulares para producir proteina c activada.
ATE122150T1 (de) Einschritt-immuntest zur bestimmung von antigen- spezifischen antikörpern aller immunglobulin- klassen und dazu geeignetes mittel.
Lim et al. Effect of Placental Serum to Cultures of the Healthy Human Peripheral Blood Lymphocytes
Kloosterman This fee includes a copy of the final program, an abstracts volume; a copy of the Proceedings; part of the social events and refreshments during the breaks. Wagons-Lits Tours, Cantersteen 41, B-lOOO-Brussels has been ap-pointed the Official Travel Agent. All correspondence should be sent to
Agent et al. Laboratory of Pharmaceu tical Chemistry and Drug Analysis State University of Ghent Harelbekestraat 72 B-9000-Ghen t (Belgium)
EP1097174A4 (de) Antikoagulierender antikörper aus lupus gegen die f1 region von prothrombin
Warden Immunoassays for veterinary and food analysis, vol. 1 (edited by BA Morris, MN Clifford and R. Jackman): Elsevier, Barking, 1988,£ 54.00 (vii+ 392 pages) ISBN 1-85166-138-7
Cinader Immunodiagnostic tests for cancer
Anderson Myths and Legends from Korea: An Annotated Compendium of Ancient and Modern Materials
KR880013012A (ko) 항-프리-s- 항체의 분석법
Padmanabhan Mechanism of action of enhanced antibody dependent cellular cytotoxicity in a mammary tumor model system

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties